Belite Bio initiates NDA submission for tinlarebant in Stargardt disease type 1

Belite Bio has initiated a rolling New Drug Application (NDA) submission to the US FDA for tinlarebant (LBS-008), an oral investigational therapy targeting Stargardt disease type 1 (STGD1), a rare inherited retinal disorder. The filing represents the first NDA submission for a pharmacological treatment in STGD1, a condition for which no approved therapy currently exists.

The rolling submission, initiated on April 21, 2026, proceeds under Breakthrough Therapy Designation previously granted by the FDA for tinlarebant in STGD1. The rolling submission mechanism, which the FDA had pre-authorized for Belite Bio, allows completed sections of the NDA to be submitted and reviewed incrementally rather than as a single package. The company said it expects to complete the submission in Q2 2026. No PDUFA date has been announced, as the NDA has not yet been formally accepted for review.

Tinlarebant acts by inhibiting retinol binding protein 4 (RBP4), the sole carrier protein responsible for transporting vitamin A from the liver to the retina. In STGD1, mutations in the ABCA4 gene impair clearance of vitamin A byproducts within the retinal pigment epithelium, leading to accumulation of toxic bisretinoids — including A2E — that drive progressive photoreceptor degeneration. By reducing retinol delivery to the eye, tinlarebant is designed to limit bisretinoid formation upstream of this toxic accumulation.

The NDA package is anchored by data from the Phase III DRAGON trial, a 24-month, randomized, double-masked, placebo-controlled study enrolling 104 adolescents with STGD1, with subjects allocated 2:1 to tinlarebant or placebo. The trial's primary endpoint was the growth rate of macular atrophic lesions, quantified as definitely decreased autofluorescence (DDAF) on fundus autofluorescence imaging — a structural measure that has become the field's accepted surrogate for disease progression, given the insensitivity of visual acuity as a short-term endpoint in STGD1.

The company reported that DRAGON met its primary endpoint, with tinlarebant reducing lesion growth by 35.7% compared with placebo (p=0.0033). A post hoc analysis yielded a comparable treatment effect of 35.4% with p<0.0001, the company said. These results, released in late 2025, were described by Belite Bio as the first successful pivotal trial readout in STGD1.

The absence of any approved treatment for STGD1 frames the regulatory and clinical significance of this filing. The disease, caused by autosomal recessive mutations in ABCA4, typically manifests in childhood or adolescence and progresses to legal blindness in the majority of cases. Current management is limited to supportive measures — avoidance of high-dose vitamin A supplementation, UV light protection, and low vision rehabilitation — none of which have demonstrated efficacy in slowing lesion progression in controlled trials. The FDA's prior grant of Breakthrough Therapy Designation to tinlarebant reflects the agency's own assessment of the unmet need in this population.

Tinlarebant also carries Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in the US, as well as Orphan Drug Designation in Europe and Japan, and Sakigake Designation in Japan. The breadth of these designations reflects both the rarity of STGD1 — affecting an estimated one in 8,000 to 10,000 individuals — and the absence of competing approved therapies.

---

Spot something wrong? Report an issue with this article